View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 30, 2022

Evotec to acquire cell technology firm Rigenerand

The deal will add the Evotec EVOcells cell therapy platform to Rigenerand’s cGMP manufacturing site.

Evotec has entered a definitive agreement for the acquisition of 100% of the capital of Italy-based cell technology firm Rigenerand for $24.7m (€23m).

Founded as a spin-off of the University of Modena and Reggio Emilia in 2009, Rigenerand focuses on the cGMP manufacturing of cell therapies.

The company runs a certified production facility that merges cGMP manufacturing with research and development (R&D) and QC labs, as well as development labs.

Called ‘cell factory’, the plant consists of a series of fully equipped clean rooms to produce complex cell-based therapies.

Situated in Medolla, Italy, the site comprises 1,200m² of high-tech production space, which can be further expanded.

Through the acquisition, Evotec will add a team of cell therapy cGMP manufacturing experts.

The deal will add the cell therapy platform of Evotec, EVOcells, to a cGMP manufacturing site.

The merging of discovery and development of new cures, along with in-house expertise in GMP production, is required within this field.

Even though the revenue contribution might not be substantial in the initial stage, the production expertise of Rigenerand, together with Evotec’s R&D capability, will improve the latter’s ability to enter new, integrated collaborations within the cell therapy field.

Evotec CEO Dr Werner Lanthaler said: “Cell therapies are an exciting emerging therapeutic modality, with broad applicability across many indications.

“Originating from our leading iPSC platform, Evotec’s EVOcells platform enables the delivery of innovative cell therapeutics from inception to the patient.

“The acquisition of Rigenerand adds manufacturing capacity and expertise to the EVOcells platform.”

The company developed EVOcells as an integrated, versatile platform to discover, develop and, produce cell therapies.

EVOcells project portfolio of Evotec includes immuno-oncology, metabolic diseases, heart repair, and exosome-based therapies.

The latest development comes after Evotec and Sernova entered an exclusive worldwide strategic partnership to develop cell therapy for insulin-dependent diabetes.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology